2685.HK
Baozun does e-commerce tools

Shares of online consumer website operator Quantgroup Holding Ltd. (2685.HK) opened up 165% in their Hong Kong trading debut on Thursday, and held on to much of the gains to close up 89% at HK$18.50 at the end of their first trading day.

The company sold 13.35 million shares for HK$9.80 apiece, representing the top of their range. The public portion of the offering for local Hong Kong investors was 9,365 times oversubscribed, while the international tranche was 14 times oversubscribed.

Quantgroup operates two core businesses: its Yangxiaomie lifestyle platform, and its online-to-offline (O2O) auto retail Consumption Guide. Its net profit for 2024 surged nearly 40-fold year-on-year to 147 million yuan ($20.76 million), primarily driven by strong revenue growth from Yangxiaomie. For the first five months of this year, its profit jumped 170% year-on-year to 126 million yuan.

The company raised a modest HK$131 million in gross proceeds from the listing, but most of that was used to pay for listing expenses. After deducting such expenses, it generated just HK$12.37 million in net proceeds from the listing.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…